Market Intelligence, Synthetic Lethality Strategies, and High-Purity Kinase Reagents for G2 Checkpoint Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PKMYT1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PKMYT1 Active Kinase Protein Full-length or Catalytic Domain. Sequence Verified, >95% Purity, Theoretical MW, Endotoxin <1EU/µg. ATP-binding validated by structural modeling. |
View PKMYT1 Products |
| Gene Delivery | PKMYT1 ORF / Lentivirus Full-length ORF for stable cell line construction. HEK293 expressed. |
View PKMYT1 Products |
| Benchmark Ab | Anti-PKMYT1 (Clone Reference) Recombinant monoclonal for Western/IP control. Sequence Verified. |
View PKMYT1 Products |
| Validator | PKMYT1 siRNA Set For specific knockdown and synthetic lethality validation. |
View PKMYT1 Products |
| Related Target: WEE1 | WEE1 Kinase Synthetic lethality partner. Required for combination screening assays. |
View WEE1 Products |
| Related Target: CDK1 | CDK1/Cyclin B1 Complex Direct substrate for PKMYT1 kinase activity assays. |
View CDK1 Products |
| Related Target: CCNE1 | Cyclin E1 Biomarker for patient stratification in CCNE1-amplified cancers. |
View CCNE1 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| WEE1/PKMYT2 Selectivity Screening | Active PKMYT1, WEE1, and PKMYT2 proteins with >95% purity. Ortholog panels for cross-species kinase selectivity. |
| Drug Resistance Profiling | PKMYT1 Mutant Library (Gatekeeper and Activation Loop variants). Sequence Verified. |
| Substrate Phosphorylation Assay | CDK1/Cyclin B1 complex available as substrate. Phospho-CDK1(Tyr15) detection ready. |
| Synthetic Lethality Validation | Dual-promoter Lentiviruses for PKMYT1/WEE1 co-knockdown. siRNA sets for both targets. |
Live PKMYT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PKMYT1 therapeutics is intensifying, driven by the discovery of its synthetic lethal relationship with CCNE1 amplification in solid tumors. Major players include Repare Therapeutics (lunresertib/RP-6306, partnered with Roche), Iksuda Therapeutics (ICR-6948), Trojan Therapeutics (TP-1287), and Designate Therapeutics (DSN-210). As first-generation WEE1 inhibitors face resistance mechanisms, PKMYT1 has emerged as a critical collateral target. Combination therapies with ATR or WEE1 inhibitors represent a major strategic focus. The next wave of R&D is targeting brain-penetrant inhibitors for CNS metastases and resistance-bypass mutations.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Repare Therapeutics, Roche, Iksuda (ICR-6948), Trojan (TP-1287), Designate (DSN-210) | Ovarian Cancer (CCNE1 amp), NSCLC | Kinase Selectivity Panel (Need WT vs WEE1/PKMYT2 active proteins) |
| PROTAC Degrader | Emerging Academic/Biotech | Solid Tumors | Binary/Ternary Complex Formation (Need high-affinity ligands) |
| Combination Therapy | AstraZeneca (WEE1 combinations), Multiple Biopharmas | Refractory Solid Tumors, Endometrial/Ovarian Cancers | Synthetic Lethality Validation (Need dual-target siRNA & cell lines) |